Source: Virtual Congress 2021 – Advances in asthma treatment



Rating:

Share or cite this content

Citations should be made in the following way:
C. Pilette (Bruxelles, Belgium), G. Canonica (Milan, Italy), R. Chaudhuri (Glasgow, United Kingdom), F. Lee (Atlanta, GA, United States of America), J. Lee (Toronto, ON, Canada), C. Almonacid Sanchez (Madrid, Spain), R. Alfonso-Cristancho (Collegeville, PA, United States of America), R. Jakes (London , United Kingdom), A. Maxwell (Stevenage, United Kingdom), R. Price (Stevenage, United Kingdom), P. Howarth (Brentford, United Kingdom). Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A. 3539

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Longitudinal analysis of variation in clinical features from the U-BIOPRED severe asthma cohort Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Occupational exposure to disinfectants and COPD incidence in US nurses: a prospective cohort study Source: International Congress 2017 – The air indoor air pollution Year: 2017 Late Breaking Abstract - 1-year radiological, functional and quality-of-life outcomes in patients with SARS-CoV-2 pneumonia: A prospective observational study. Source: Virtual Congress 2021 – Respiratory infections Year: 2021 An Italian, observational, multicenter trial in female COPD patients: Preliminary data on the women reality in the MISTRAL study Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Late Breaking Abstract - Reslizumab vs benralizumab in patients with inadequately controlled asthma: a Bayesian network meta-analysis Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Cardiovascular risk and COPD in a population-based study Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Late Breaking Abstract - Tocilizumab administration for the treatment of hospitalised patients with COVID-19: A systematic review and meta-analysis Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021 Late Breaking Abstract - SABA overuse and risk of mortality in a nationwide Swedish asthma cohort (HERA) Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - IPF symptoms’ course during a 3-month observation: FIBRONET observational study’s preliminary results. Source: International Congress 2017 – Miscellaneous clinical problems Year: 2017 Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Pharmacological and clinical management of severe asthma in 9 countries: An international survey of clinicians. Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020